Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention

Research conducted during the past 30 years has increased our understanding of the mechanisms involved in colorectal cancer initiation and development. The findings have demonstrated the existence of at least three pathways: chromosomal instability, microsatellite instability and CpG island methylator phenotype. Importantly, new studies have shown that inflammation and microRNAs contribute to colorectal carcinogenesis. Recent data have demonstrated that several genetic and epigenetic changes are important in determining patient prognosis and survival. Furthermore, some of these mechanisms are related to patients’ response to drugs, such as aspirin, which could be used for both chemoprevention and treatment in specific settings. Thus, in the near future, we could be able to predict disease behavior based on molecular markers found on tumors, and direct the best treatment options for patients.

[1]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[2]  Y. Nakamura,et al.  Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. , 1989, JAMA.

[3]  M. Leppert,et al.  Allelic Loss in Colorectal Carcinoma , 1989 .

[4]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[5]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[6]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[7]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[8]  A. Andrén-sandberg,et al.  Cytogenetic analysis of 52 colorectal carcinomas‐‐non‐random aberration pattern and correlation with pathologic parameters , 1993, International journal of cancer.

[9]  K. Kinzler,et al.  Molecular diagnosis of familial adenomatous polyposis. , 1993, The New England journal of medicine.

[10]  H T Lynch,et al.  Hereditary Nonpolyposis Colorectal Cancer Patients Replication Errors in Benign and Malignant Tumors from , 2006 .

[11]  P. Traber,et al.  Cancer in inflammatory bowel disease. , 1994, The Medical clinics of North America.

[12]  O. Kronborg,et al.  Karyotypic characterization of colorectal adenocarcinomas , 1995, Genes, chromosomes & cancer.

[13]  T. Kunkel,et al.  Microsatellite instability and mismatch repair defects in cancer cells , 1996 .

[14]  H. Hibshoosh,et al.  Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. , 1996, Gastroenterology.

[15]  Irene L Andrulis,et al.  MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma , 1996, Cell.

[16]  T. Kunkel,et al.  Microsatellite instability and mismatch repair defects in cancer. , 1996, Mutation research.

[17]  B. Leggett,et al.  Microsatellite instability in the insulin–like growth factor II receptor gene in gastrointestinal tumours , 1996, Nature Genetics.

[18]  E. Torlakovic,et al.  Serrated adenomatous polyposis in humans. , 1996, Gastroenterology.

[19]  K. Kinzler,et al.  Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients , 1996, Nature Medicine.

[20]  H. Yamamoto,et al.  Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. , 1997, Cancer research.

[21]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[22]  K. Kinzler,et al.  Frequency of Smad gene mutations in human cancers. , 1997, Cancer research.

[23]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[24]  M. Loda,et al.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.

[25]  Bert Vogelstein,et al.  Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .

[26]  L. Myeroff,et al.  Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. , 1998, Cancer research.

[27]  A. Sparks,et al.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. , 1998, Cancer research.

[28]  R. Fishel.  Mismatch repair, molecular switches, and signal transduction. , 1998, Genes & development.

[29]  T. Iwama,et al.  Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas. , 1998, Gastroenterology.

[30]  R. Gafà,et al.  Chromosome 18q allelic loss and prognosis in stage II and III colon cancer , 1998, International journal of cancer.

[31]  J. Herman,et al.  Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. , 1998, Cancer research.

[32]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[34]  L. Kasturi,et al.  Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Tytell,et al.  Germ-line msh6 mutations in colorectal cancer families. , 1999, Cancer research.

[36]  G. Chan,et al.  Human Bubr1 Is a Mitotic Checkpoint Kinase That Monitors Cenp-E Functions at Kinetochores and Binds the Cyclosome/APC , 1999, The Journal of cell biology.

[37]  J. Jessup,et al.  Interleukin-6 Blood Level Is Associated With Circulating Carcinoembryonic Antigen and Prognosis in Patients With Colorectal Cancer , 2000, Annals of Surgical Oncology.

[38]  I. Nenci,et al.  Genetic progression in microsatellite instability high (MSI‐H) colon cancers correlates with clinico‐pathological parameters: A study of the TGRβRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes , 2000, International journal of cancer.

[39]  G. Capellá,et al.  K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. , 2000, Cancer research.

[40]  S. Goodman,et al.  Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. , 2001, Cancer research.

[41]  L. Lipton,et al.  Whole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or “multiple” colorectal adenomas , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Gafà,et al.  Immunohistochemical Pattern of MLH1/MSH2 Expression Is Related to Clinical and Pathological Features in Colorectal Adenocarcinomas with Microsatellite Instability , 2002, Modern Pathology.

[43]  T. Tomonaga,et al.  Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. , 2003, Cancer research.

[44]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[45]  C. R. Herzog,et al.  Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. , 2003, Cancer research.

[46]  F. McKeon,et al.  Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. , 2003, Cancer cell.

[47]  Wei Zhao,et al.  BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. , 2003, Cancer research.

[48]  Jen‐Kou Lin,et al.  Loss of Heterozygosity and DNA Aneuploidy in Colorectal Adenocarcinoma , 2003, Annals of Surgical Oncology.

[49]  L. Lipton,et al.  Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. , 2003, The New England journal of medicine.

[50]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[51]  R. Sandler,et al.  Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. , 2004, Gastroenterology.

[52]  N. Matsubara,et al.  BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum , 2004, Gut.

[53]  K. Jones,et al.  Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. , 2004, Molecular cell.

[54]  L. Kolonel,et al.  A case-control study of diet and colorectal cancer in a multiethnic population in Hawaii (United States): lipids and foods of animal origin , 1997, Cancer Causes & Control.

[55]  Shan Wang,et al.  Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. , 2004, World journal of gastroenterology.

[56]  Zhiyong Ma,et al.  Transcriptional Control of BubR1 by p53 and Suppression of Centrosome Amplification by BubR1 , 2005, Molecular and Cellular Biology.

[57]  F. Bazzoli,et al.  High Thymidylate Synthase Expression in Colorectal Cancer with Microsatellite Instability: Implications for Chemotherapeutic Strategies , 2005, Clinical Cancer Research.

[58]  L. Hooper.  Faculty Opinions recommendation of Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. , 2005 .

[59]  Kurt Zatloukal,et al.  Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. , 2005, Neoplasia.

[60]  R. Wolff,et al.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. , 2005, Gastroenterology.

[61]  E. J. Lee,et al.  Progressive methylation during the serrated neoplasia pathway of the colorectum , 2005, Modern Pathology.

[62]  M. Washington,et al.  Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  T. Tomonaga,et al.  Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. , 2005, Cancer research.

[64]  A. Tamakoshi,et al.  Colorectal Cancer and Serum C-reactive Protein Levels: a Case-control Study Nested in the JACC Study , 2005, Journal of epidemiology.

[65]  X. Agirre,et al.  Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues , 2006, Molecular Cancer.

[66]  J. Jass,et al.  Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer , 2006, Histopathology.

[67]  M. Inoue,et al.  Plasma C-Reactive Protein and Risk of Colorectal Cancer in a Nested Case-Control Study: Japan Public Health Center–Based Prospective Study , 2006, Cancer Epidemiology Biomarkers & Prevention.

[68]  R. Sinha,et al.  A prospective study of serum C-reactive protein and colorectal cancer risk in men. , 2006, Cancer research.

[69]  T. Takayama,et al.  Colorectal cancer: genetics of development and metastasis , 2006, Journal of Gastroenterology.

[70]  Rozemary Karamatic,et al.  High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. , 2006, Gastroenterology.

[71]  D. Qualtrough,et al.  Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. , 2006, Cancer research.

[72]  M. Loda,et al.  Correlation of Pathologic Features With CpG Island Methylator Phenotype (CIMP) by Quantitative DNA Methylation Analysis in Colorectal Carcinoma , 2006, The American journal of surgical pathology.

[73]  Brian S. Roberts,et al.  The colorectal microRNAome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[74]  M. O'brien,et al.  Comparison of Microsatellite Instability, CpG Island Methylation Phenotype, BRAF and KRAS Status in Serrated Polyps and Traditional Adenomas Indicates Separate Pathways to Distinct Colorectal Carcinoma End Points , 2006, The American journal of surgical pathology.

[75]  M. Loda,et al.  Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. , 2007, Human pathology.

[76]  M. Loda,et al.  Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP , 2007, Modern Pathology.

[77]  P. Møller,et al.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) , 2007, Journal of Medical Genetics.

[78]  J. Alao,et al.  Molecular Cancer BioMed Central Review The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention , 2007 .

[79]  George A Calin,et al.  mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer , 2007, Molecular Cancer.

[80]  Minoru Toyota,et al.  Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer , 2007, Proceedings of the National Academy of Sciences.

[81]  D. Chang,et al.  The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch Syndrome: from bench to bedside , 2007, Familial Cancer.

[82]  M. Loda,et al.  Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. , 2007, Human pathology.

[83]  J. Meyerhardt,et al.  Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer , 2007, Gut.

[84]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[85]  G. Parmigiani,et al.  Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers , 2008, Proceedings of the National Academy of Sciences.

[86]  S. Ogino,et al.  LINE‐1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer , 2008, International journal of cancer.

[87]  S. Ogino,et al.  Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype , 2008, Histopathology.

[88]  E. Giovannucci,et al.  Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer , 2008, Clinical Cancer Research.

[89]  S. Ogino,et al.  PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. , 2008, Neoplasia.

[90]  J. Meyerhardt,et al.  CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci , 2008, Modern Pathology.

[91]  Pablo Tamayo,et al.  CDK8 is a colorectal cancer oncogene that regulates β-catenin activity , 2008, Nature.

[92]  Feng Yang,et al.  Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. , 2009, The New England journal of medicine.

[93]  Shuji Ogino,et al.  p21 Expression in Colon Cancer and Modifying Effects of Patient Age and Body Mass Index on Prognosis , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[94]  C. Huttenhower,et al.  Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors , 2010, Molecular Cancer.

[95]  M. Batzer,et al.  The impact of retrotransposons on human genome evolution , 2009, Nature Reviews Genetics.

[96]  J. Meyerhardt,et al.  Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Shuji Ogino,et al.  DNMT3B Expression Might Contribute to CpG Island Methylator Phenotype in Colorectal Cancer , 2009, Clinical Cancer Research.

[98]  H. Knüpfer,et al.  Serum interleukin-6 levels in colorectal cancer patients—a summary of published results , 2010, International Journal of Colorectal Disease.

[99]  K. Mimori,et al.  Over- and under-expressed microRNAs in human colorectal cancer. , 2009, International journal of oncology.

[100]  Shuji Ogino,et al.  A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases , 2009, Clinical Cancer Research.

[101]  Shuji Ogino,et al.  MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers , 2011, Cancer Causes & Control.

[102]  Yong-jig Cho,et al.  Antimetastatic role of Smad4 signaling in colorectal cancer. , 2010, Gastroenterology.

[103]  Wolfram Goessling,et al.  PTGER2 Overexpression in Colorectal Cancer Is Associated with Microsatellite Instability, Independent of CpG Island Methylator Phenotype , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[104]  Shuji Ogino,et al.  CDK8 expression in 470 colorectal cancers in relation to β‐catenin activation, other molecular alterations and patient survival , 2010, International journal of cancer.

[105]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[106]  Shuji Ogino,et al.  Cathepsin B Expression and Survival in Colon Cancer: Implications for Molecular Detection of Neoplasia , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[107]  J. Meyerhardt,et al.  HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. , 2010, The American journal of pathology.

[108]  Hiroyuki Yamamoto,et al.  IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. , 2010, Carcinogenesis.

[109]  M. Loda,et al.  Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer , 2010, British Journal of Cancer.

[110]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[111]  Y. Samuels,et al.  Oncogenic mutations of PIK3CA in human cancers. , 2004, Current topics in microbiology and immunology.

[112]  M. Sanz,et al.  Frequency of Rearrangements in Lynch Syndrome Cases Associated with MSH2: Characterization of a New Deletion Involving both EPCAM and the 5′ Part of MSH2 , 2011, Cancer Prevention Research.

[113]  Chulan Kwon,et al.  Notch Post-Translationally Regulates β-Catenin Protein in Stem and Progenitor Cells , 2011, Nature Cell Biology.

[114]  J. Meyerhardt,et al.  TGFBR2 and BAX Mononucleotide Tract Mutations, Microsatellite Instability, and Prognosis in 1072 Colorectal Cancers , 2011, PloS one.

[115]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[116]  D. Bishop,et al.  A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis , 2011, Cancer Prevention Research.

[117]  Q. Lin,et al.  R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/β-catenin signaling , 2011, Proceedings of the National Academy of Sciences.

[118]  S. Söldner-Rembold,et al.  The first 30 years , 1983 .

[119]  E. Giovannucci,et al.  Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. , 2011, Gastroenterology.

[120]  Shuji Ogino,et al.  Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review , 2011, International journal of cancer.

[121]  Reiko Nishihara,et al.  Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers , 2012, Clinical Cancer Research.

[122]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[123]  Reiko Nishihara,et al.  Tumor TP53 expression status, body mass index and prognosis in colorectal cancer , 2012, International journal of cancer.

[124]  D. Sargent,et al.  Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications , 2012, Clinical Cancer Research.

[125]  Shuji Ogino,et al.  Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. , 2012, Cancer research.

[126]  A. Spurdle,et al.  Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.

[127]  E. Steyerberg,et al.  Comparison of the clinical prediction model PREMM1,2,6 and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer , 2012, Gut.

[128]  Karan P. Singh,et al.  The Prognostic Value of MicroRNAs Varies with Patient Race/Ethnicity and Stage of Colorectal Cancer , 2013, Clinical Cancer Research.

[129]  F. Berrino,et al.  Italian mediterranean index and risk of colorectal cancer in the Italian section of the EPIC cohort , 2013, International journal of cancer.

[130]  Reiko Nishihara,et al.  Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status. , 2013, Cancer research.

[131]  E. Giovannucci,et al.  A prospective study of plasma inflammatory markers and risk of colorectal cancer in men , 2013, British Journal of Cancer.

[132]  D. Spiegelman,et al.  Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. , 2013, Journal of the National Cancer Institute.

[133]  M. Washington,et al.  PIK3CA and APC mutations are synergistic in the development of intestinal cancers , 2014, Oncogene.